Axsome Therapeutics Inc (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for the treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07-migraine, AXS-12-narcolepsy, and AXS-14, for the treatment of fibromyalgia. Its other products include sunosi and auvelity. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York City, New York, the US.
Axsome Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
AXS-14-Fibromyalgia |
AXS-05-Alzheimer Disease |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Plans/Strategy | In June, the company announced its plans to sell its shares of its common stock in an underwritten public offering. |
2023 | Contracts/Agreements | In February, the company entered into a license agreement with Pharmanovia to commercialize and further develop Sunosi. |
2022 | New Products/Services | In November, the company announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist. |
Competitor Comparison
Key Parameters | Axsome Therapeutics Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | GSK plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
City | New York | Kenilworth | New York | North Chicago | Brentford |
State/Province | New York | New Jersey | New York | Illinois | England |
No. of Employees | 383 | 69,000 | 88,000 | 50,000 | 69,400 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Herriot Tabuteau | Chief Executive Officer; Chairman | Executive Board | 2012 | 54 |
Nick Pizzie | Chief Financial Officer | Senior Management | 2018 | 48 |
Mark Jacobson | Chief Operating Officer | Senior Management | 2020 | 39 |
Hunter Murdock | Executive Vice President - Legal and Compliance | Senior Management | 2021 | - |
Lori Englebert | Senior Vice President - Commercial and Business Development | Senior Management | 2020 | 45 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward